CYP7A1, NPC1L1, ABCB1, and CD36 Polymorphisms Are Associated with Increased Serum Coenzyme Q$_{10}$ after Long-Term Supplementation in Women

Michiyo Takahashi $^{1}$*, Mayumi Nagata $^{2}$, Tetsu Kinoshita $^{3,4}$, Takehiko Kaneko $^{1,2}$ and Toshikazu Suzuki $^{1,2,*}$

1 Graduate School of Human Ecology, Wayo Women’s University, 2-3-1 Konodai, Ichikawa, Chiba 272-8533, Japan; michiyo.takahashi1202@gmail.com (M.T.); t-kaneko@wayo.ac.jp (T.K.)
2 Department of Health and Nutrition, Wayo Women’s University, 2-3-1 Konodai, Ichikawa, Chiba 272-8533, Japan; k11.clover13@gmail.com
3 Special Course of Food and Health Science, Department of Bioscience Graduate School of Agriculture, Ehime University, 3-5-7 Tarumi, Matsuyama, Ehime 790-8566, Japan; tetsu@shin-science.co.jp
4 Institute of Community Life Sciences Co., Ltd., 1383-2 Hiramachi, Matsuyama, Ehime 791-0243, Japan
* Correspondence: t-suzuki@wayo.ac.jp; Tel.: +81-47-371-1547

Abstract: Coenzyme Q$_{10}$ (CoQ$_{10}$), an essential component for energy production that exhibits antioxidant activity, is considered a health-supporting and antiaging supplement. However, intervention-controlled studies have provided variable results on CoQ$_{10}$ supplementation benefits, which may be attributed to individual CoQ$_{10}$ bioavailability differences. This study aimed to investigate the relationship between genetic polymorphisms and CoQ$_{10}$ serum levels after long-term supplementation. CoQ$_{10}$ levels at baseline and after one year of supplementation (150 mg) were determined, and eight single nucleotide polymorphisms (SNPs) in cholesterol metabolism and CoQ$_{10}$ absorption, efflux, and cellular uptake related genes were assessed. Rs2035282 (ABCB1) and rs1761667 (CD36) were significantly associated with a higher increase in CoQ$_{10}$ levels in women. In addition, in women, rs3808607 (CYP7A1) and rs2072183 (NPC1L1) were significantly associated with a higher increase in CoQ$_{10}$ per total cholesterol levels. Subgroup analyses showed that these four SNPs were useful for classifying high- or low-responder to CoQ$_{10}$ bioavailability after long-term supplementation among women, but not in men. On the other hand, in men, no SNP was found to be significantly associated with increased serum CoQ$_{10}$. These results collectively provide novel evidence on the relationship between genetics and CoQ$_{10}$ bioavailability after long-term supplementation, which may help understand and assess CoQ$_{10}$ supplementation effects, at least in women.

Keywords: bioavailability; cholesterol; coenzyme Q$_{10}$; single nucleotide polymorphisms

1. Introduction

Coenzyme Q$_{10}$ (CoQ$_{10}$) is a vitamin-like molecule that is involved in ATP synthesis in mitochondria and is a crucial antioxidant that protects against oxidative damages of cell membranes and lipoproteins [1–3]. CoQ$_{10}$ supplementation slowed aging and decreased protein, lipid, and DNA oxidative damage in the senescence-accelerated mouse prone 1 mice [4,5]. Similarly, reduced DNA oxidative damage by CoQ$_{10}$ supplementation was observed in male Wistar rats [6]. In addition, CoQ$_{10}$ supplementation ameliorated fatigue and promoted exercise performance, possibly by combining enhanced energy production in mitochondria and enhanced antioxidant protection, in male Institute of Cancer Research mice [7]. Human interventional studies also suggest the beneficial effects of CoQ$_{10}$, including anti-inflammatory activities, prevention or improvement of degenerative disorders affecting longevity [8], enhanced vitality of patients undergoing medical treatment as well as on elderly residents of nursing homes [9–11], and alleviation of fatigue in patients with chronic fatigue syndrome [12,13]. Hence, CoQ$_{10}$ is considered a health-supporting and antiaging supplement. However, meta-analyses of these studies provided inconsistent
results related to the effects of CoQ<sub>10</sub> supplementation [14–17] and even failed to show any beneficial effect of CoQ<sub>10</sub> supplementation [14–16]. Hence, further studies are required to produce substantial clinical evidence supporting the benefits of CoQ<sub>10</sub> supplementation [18].

One of the challenges to generate reliable evidence for the beneficial effects of CoQ<sub>10</sub> supplementation is its low bioavailability due to poor water solubility and high molecular weight. Several types of CoQ<sub>10</sub> delivery systems and a stable capsule-based product containing ubiquinol (the reduced form of CoQ<sub>10</sub>) were developed to increase the bioavailability of supplemental CoQ<sub>10</sub> [19–24]. However, considerable variation and high standard derivations were reported for the single-dose pharmacokinetics and bioavailability of CoQ<sub>10</sub> [22,23]. A large variance in the serum CoQ<sub>10</sub> levels was also observed after long-term CoQ<sub>10</sub> supplementation [25,26], suggesting that such variances may be another reason to affect the accurate recognition of the beneficial effects of CoQ<sub>10</sub>.

The absorption of supplemental CoQ<sub>10</sub> into the bloodstream [27] starts with enterocytes absorbing CoQ<sub>10</sub> in the intestine with the aid of carrier molecules/proteins on the cell membrane. The cholesterol transporter Niemann–Pick C1-like 1 (NPC1L1) protein is a candidate molecule to contribute to the absorption process [28,29]. Next, the CoQ<sub>10</sub> molecules are incorporated into chylomicrons, which circulate in the lymph and blood, carrying the CoQ<sub>10</sub> to the liver, where it is attached to the low-density and very-low-density lipoproteins. Then, the CoQ<sub>10</sub> returns to the bloodstream as a lipoprotein complex. Hence, serum CoQ<sub>10</sub> levels correlate strongly and positively with serum cholesterol levels [30]. Some exogenous CoQ<sub>10</sub> can also be incorporated into cells, although the exact mechanism remains unclear [31]. Recently, Anderson et al. reported that the scavenger receptor CD36 drives the uptake of CoQ<sub>10</sub> in brown adipose tissue, where it is required for normal physiological function [32]. In turn, the ATP-binding cassette subfamily B member 1 (ABCB1) expressed in enterocytes may excrete the absorbed CoQ<sub>10</sub> into the intestinal lumen [33]. Thus, several proteins involved in CoQ<sub>10</sub> absorption/incorporation and cholesterol metabolism adjust the individual serum CoQ<sub>10</sub> levels during supplementation.

The involvement of genetic polymorphism in the pharmacokinetic profile, bioavailability, and metabolism of various drugs and nutrients has been reported in the last two decades. For example, single nucleotide polymorphisms (SNPs) and haplotypes of ABCB1 are associated with altered drug disposition, drug response, and toxicity [34]. CD36 SNPs and haplotypes are associated with serum LDL and total cholesterol levels [35]. Recently, Tomei et al. reported that rs731236 in the vitamin D receptor (VDR) gene and rs7116978 in the cytochrome p450 family 2 subfamily R member 1 (CYP2R1) gene were associated with serum 25-hydroxyvitamin D levels, the primary circulating form of vitamin D, after 12 weeks of vitamin D supplementation [36]. Only a few studies have reported an association between genetic polymorphism and basal serum CoQ<sub>10</sub> status in humans [37,38] and increased serum CoQ<sub>10</sub> levels after the two-week supplementation [38], but there is no study reporting the association after long-term supplementation.

In this study, the impact of polymorphisms in genes potentially involved in CoQ<sub>10</sub> bioavailability on serum CoQ<sub>10</sub> levels after long-term supplementation was evaluated in volunteers of the Ubiquinol Health Examination, a prospective intervention trial held in the Ehime Prefecture, Japan [26,39]. The SNPs were assessed in the following genes involved in the cholesterol metabolism: sterol regulatory element-binding protein 2 (SREBP2), 3-hydroxy-3-methylglutaryl–coenzyme A reductase (HMGCR), apolipoprotein B (APOB), cytochrome P450 family 7 subfamily A member 1 (CYP7A1), and CoQ<sub>10</sub> absorption (NPC1L1), excretion (ABCB1), and cellular uptake (CD36). We further investigated whether genotyping of SNPs in the above genes is useful for classifying high- or low-responder to CoQ<sub>10</sub> bioavailability after long-term supplementation.
2. Materials and Methods

2.1. CoQ<sub>10</sub> Supplementation

Two types of reduced CoQ<sub>10</sub> (ubiquinol) supplements (soft-encapsulated and granulated form) were provided by the Kaneka Co. (Osaka, Japan). The soft capsule Kaneka QHTM contains reduced CoQ<sub>10</sub> (50 mg per capsule), rapeseed oil, beeswax, soy lecithin, polyglycerol esters of fatty acids, gelatin, glycerol, and caramel. The granulated form P30 contains 30% (w/w) reduced CoQ<sub>10</sub> (150 mg per sachet), dextrin, gum Arabic, and L-ascorbate. The participants could choose either the capsule or the granulated form of the supplement, taking three capsules or one sachet per day, respectively, corresponding to a daily dose of 150 mg CoQ<sub>10</sub> during the intervention trial. The participants also could switch between supplement types every three months.

2.2. Study Design

A total of 170 participants who had been participating in the “Verification of health enhancement and QOL improvement effect by continuous ubiquinol ingestion (Ubiquinol Health Examination)” study (UMIN000012612) [26,39] were recruited (Figure 1). All participants were residents of Kamijima-town of Ehime Prefecture, Japan. Kamijima consists of 25 small islands located in the Seto Inland Sea. Since Kamijima is a super-aging region (population aging rate is more than 40%), the authors considered Kamijima was appropriate to evaluate the effects of antiaging materials such as CoQ<sub>10</sub>. The participants took 150 mg per day of reduced CoQ<sub>10</sub> in the postprandial state (after breakfast or lunch) from November 2016 to November 2017. First blood samples were collected at the time of enrollment in the Kamijima Ubiquinol Health Examination study (from November 2013 to November 2016), which served as a baseline, and another sample was collected in November 2017, after 1 year of 150 mg reduced CoQ<sub>10</sub> supplementation. All participants provided informed consent before they participated in this study. This study was conducted in accordance with the Declaration of Helsinki, and it was approved by the Wayo Women’s University Human Research Ethics Committee (No. 1614). Participants were excluded from the analysis if the increased serum CoQ<sub>10</sub> levels were less than 1 μmol/L.

![Flow chart describing the study design.](image-url)
2.3. Measurements of Serum CoQ\textsubscript{10} and Total Cholesterol

A non-fasting blood sample was drawn between 9:00 and 15:00 on the test day when it was convenient for each participant. Blood serum was prepared by centrifugation at 3000 rpm for 10 min. For quantification of serum CoQ\textsubscript{10} levels, 0.1 mL of serum was mixed with 0.7 mL 2-propanol and stored at $-80 \, ^\circ\text{C}$ until just before the analysis. Quantitative analysis of serum CoQ\textsubscript{10} concentration was performed by Kaneka Techno Research Co. (Osaka, Japan) using liquid chromatography with tandem mass spectrometry (LC/MS/MS), as described previously [40,41].

Serum total cholesterol (TC) levels were determined enzymatically (cholesterol esterase-cholesterol oxidase-peroxidase system) at Shikoku Chuken, Inc. (Kagawa, Japan).

2.4. Polymerase Chain Reaction (PCR)-Restriction Fragment Length Polymorphism (RFLP) Genotyping

Genomic DNA was isolated from the whole blood samples using the Maxwell RSC Blood DNA kit and the Maxwell RSC Instrument (Promega Corporation. Madison, WI, USA), according to the manufacturer’s instructions. DNA concentrations were determined using Qubit dsDNA BR assay kit (Thermo Fisher Scientific, Waltham, MA, USA) and diluted to a working concentration of 10 ng/\mu L. The PCR mixtures (20 \mu L) consisted of 0.2 \mu mol/L forward and reverse primer pairs (Table 1), 0.2 mmol/L dNTP mixtures, 1 ng/\mu L template DNA, and 0.01 U/\mu L Hot-start gene Taq NT DNA polymerase (Nippon Gene Co., Toyama, Japan) in (1 ×) HS Gene Taq NT buffer. The PCR amplification was performed on a TaKaRa PCR thermal cycler dice gradient (TaKaRa Bio, Shiga, Japan), and the amplification conditions were as follows: an initial activation step of 5 min at 95 °C, 40 cycles of 30 s at 95 °C (denaturation), 30 s at 60 °C (annealing), and 1 min at 72 °C (extension), followed by a final extension for 10 min at 72 °C. Amplification was confirmed on a 2% agarose gel electrophoresis in a tris-borate-EDTA buffer. Then, residual 10 \mu L of the PCR products were directly digested overnight with an appropriate restriction enzyme (Table 1). The digested DNA fragments were electrophoretically separated on a 2% agarose gel (Nippon Gene Co.) gel. The genotypes detected by PCR-RFLP were confirmed by direct DNA sequencing of the PCR products using ABI PRISM 3100 genetic analyzer (Thermo Fisher Scientific) except for rs133291 in SREBP2.

2.5. Data Analysis

Microsoft Excel 2016 (Microsoft Corporation, Redmond, WA, USA) was used for statistical analyses. The increased serum CoQ\textsubscript{10} ($\Delta$CoQ\textsubscript{10}) and cholesterol-adjusted CoQ\textsubscript{10} (serum CoQ\textsubscript{10} per TC, $\Delta([\text{CoQ}_{10}]/\text{TC})$) levels were calculated by subtracting the baseline value from the value after supplementation. We first classified the participants into two groups by the $\Delta$CoQ\textsubscript{10} and $\Delta([\text{CoQ}_{10}]/\text{TC})$ levels to assess the association of each SNP with the response to CoQ\textsubscript{10} supplementation. The participants, whose levels were not less than the average value, were grouped as high-responders (HR), while others were grouped as low-responders (LR). A chi-squared test was performed to investigate the association and to confirm Hardy–Weinberg equilibrium (HWE) of SNP genotypes. All statistical assessments were two-tailed and considered significant at $p < 0.05$. All HWE $p$-values were more than 0.9, demonstrating that all SNPs meet HWE criteria. Welch’s $t$-test was performed when comparing the $\Delta$CoQ\textsubscript{10} and $\Delta([\text{CoQ}_{10}]/\text{TC})$ values after separating the participants by genotype into two groups.
| No. | Gene     | dbSNP ID | Major Allele | Minor Allele | Forward Primer Sequence | Reverse Primer Sequence | PCR Product Size | Restriction Enzyme | Expected Band Pattern after Digestion (Allele) |
|-----|----------|----------|--------------|--------------|-------------------------|------------------------|------------------|-------------------|-----------------------------------------------|
| 1   | SREBP2   | rs133291 | C            | T            | 5'-AAC AGT TTG ACA GCA AAG CAG A-3' | 5'-CTT TCT CTT GCC CCA TCA TTA C-3' | 381 bp          | BtgI             | 238 bp + 143 bp (C) 381 bp (T)                  |
| 2   | HMGCR    | rs3846663| C            | T            | 5'-TCA GCC TAA TCC ATT GTG TCC-3' | 5'-CTT TGC ATG CTC CTT GAA CA-3' | 333 bp          | HpyCH4III        | 150 bp + 110 bp + 73 bp (C) 183 + 150 bp (T)   |
| 3   | APOB     | rs1042034| A            | G            | 5'-TTA TCA AAA GAA GCC CAA GAG G-3' | 5'-ACG AAG GCC CAT AAT GTA TTG A-3' | 330 bp          | TspRI            | 330 bp (A)187 bp + 143 bp (G)                  |
| 4   | CYP7A1   | rs3808607| G            | T            | 5'-AAG GAT GCC ACT GAA AAG AGG G-3' | 5'-CTC TCT GGC AAA GCA CTT AAA T-3' | 441 bp          | BsaI-HF          | 221 bp + 180 bp + 40 bp (G) 261 bp + 180 bp (T) |
| 5   | NPC1L1   | rs2072183| C            | G            | 5'-AAT GAG TCC CAA GGT GAC CA-3' | 5'-ACC ACC GGG ATG ACA GAT AG-3' | 362 bp          | TaqI             | 275 bp + 87 bp (C) 362 bp (G)                  |
| 6   | ABCB1    | rs1045642| C            | T            | 5'-AAA GTG TGC TGG TCC TGA AGT T-3' | 5'-TTC TCT TCA CT TCG GGA GAC C-3' | 350 bp          | Mbol             | 172 bp + 152 bp + 26 bp (C) 324 bp + 26 bp (T) |
| 7   | ABCB1    | rs2032582| G            | T            | 5'-ATA GCA AAT CTT GGG ACA AGA A-3' | 5'-CCA AGA ACT GCC TTT GCT ACT T-3' | 352 bp          | BseYI            | 192 bp + 160 bp (G) 352 bp (T)                  |
| 8   | CD36     | rs1761667| G            | A            | 5'-GCC TCT GAA ATG CAT GTT G-3' | 5'-CGC TTT AGA ATA TTT TGG GAG A-3' | 325 bp          | HhaI             | 174 bp + 151 bp (G) 325 bp (A)                  |

Abbreviations: dbSNP ID, database single nucleotide polymorphism identifier; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism.
3. Results

Although 170 participants agreed to participate in this study, 41 dropped out during the intervention. Moreover, 21 participants whose serum ∆CoQ10 levels were less than 1 µmol/L were also excluded from the analysis, as they seemed not to follow the daily CoQ10 supplement program. Therefore, data from 108 participants were analyzed (Figure 1). The baseline characteristics of the participants are listed in Table 2.

Table 2. Baseline characteristics of the participants included in the analysis.

| Characteristics | All (n = 108) | Men (n = 38) | Women (n = 70) | p-Value |
|-----------------|--------------|-------------|---------------|---------|
| Age             | 64.2 ± 10.4  | 64.1 ± 10.9 | 64.2 ± 10.1   | 0.95    |
| CoQ10 (µmol/L)  | 1.17 ± 0.38  | 1.28 ± 0.36 | 1.11 ± 0.38   | 0.025   |
| TC (mmol/L)     | 5.09 ± 0.81  | 4.87 ± 0.88 | 5.21 ± 0.75   | 0.051   |
| CoQ10/TC (µmol/mol) | 232 ± 74  | 269 ± 82   | 213 ± 60      | 0.0005  |

Mean ± SD. p-values were analyzed by Welch’s t-test between men and women.

The ∆CoQ10 and ∆[CoQ10/TC] levels showed wide interindividual variability (Figure 2), as reported previously [26]. The mean values of the ∆CoQ10 in men and women were 5.52 and 5.05 µmol/L, while those of the ∆[CoQ10/TC] were 1110 and 952 µmol/mol, respectively. To investigate the involvement of genetic variations in the ∆CoQ10 and ∆[CoQ10/TC], eight SNPs of seven genes were evaluated (Table 1), and PCR-RFLP was performed for genotyping them in each participant (Figure S1). The genotypes identified by PCR-RFLP were also confirmed by direct sequencing, except for SREBP2 (Figure S1).

Figure 2. Serum ∆CoQ10 and ∆[CoQ10/TC] levels after 1 year of supplementation. Beeswarm boxplots of ∆CoQ10 and ∆[CoQ10/TC] for (a) men and (b) women. The bottom of the box is the 25th percentile, the line that intersects the box is the median, the multiplication sign within the box is the mean, and the top of the box is the 75th percentile. Whiskers above and below the box represent the 10th and 90th percentiles, and the points above and below the whiskers indicate the outliers. Differences between the two groups were analyzed using Welch’s t-tests (p < 0.05). ∆CoQ10, increased serum coenzyme Q10; ∆[CoQ10/TC], cholesterol-adjusted increased serum CoQ10.
To assess the association between each SNP and the response to CoQ_{10} supplementation, the participants were divided into two groups (HR and LR) according to the average ΔCoQ_{10} and Δ[CoQ_{10}/TC] levels. Among women, rs2032582 (ABCB1) and rs1761667 (CD36) were associated significantly with the HR/LR classification of ΔCoQ_{10} (chi-squared test, \( p = 0.049 \) and \( p = 0.022 \), respectively; Table 3). In addition, in women, rs3808607 (CYP7A1) and rs2072183 (NPC1L1) showed a significant association with the HR/LR classification of Δ[CoQ_{10}/TC] (chi-squared test, \( p = 0.037 \) and \( p = 0.027 \), respectively; Table 3). In contrast, none of the SNPs were associated with the HR/LR classification of ΔCoQ_{10} or Δ[CoQ_{10}/TC] in men.

### Table 3. Association of single nucleotide polymorphism (SNP) genotypes with high-responder (HR)/low-responder (LR) classification.

| SNP ID    | Gene     | Major > Minor | Men            | Women           |
|-----------|----------|---------------|----------------|-----------------|
| rs133291  | SREBP2   | C > T         | 0.93 0.24 0.19 0.31 |                 |
| rs3846663 | HMGCR    | C > T         | 0.68 0.061 0.58 0.43 |                 |
| rs1042034 | APOB     | A > G         | 0.95 0.62 0.80 0.58 |                 |
| rs3808607 | CYP7A1   | G > T         | 0.41 0.61 0.24 0.037 |                 |
| rs2072183 | NPC1L1   | C > G         | 0.48 0.46 0.10 0.027 |                 |
| rs1045642 | ABCB1    | C > T         | 0.32 0.57 0.29 0.27 |                 |
| rs2032582 | ABCB1    | G > T         | 0.66 0.57 0.049 0.053 |                 |
| rs1761667 | CD36     | G > A         | 0.13 0.36 0.022 0.075 |                 |

Abbreviations: ΔCoQ_{10}, increased serum coenzyme Q_{10}; Δ[CoQ_{10}/TC], cholesterol-adjusted increased serum CoQ_{10}; HR, high-responder; LR, low-responder; SNP, single nucleotide polymorphism.

Next, the SNPs identified with significantly low \( p \)-values of ΔCoQ_{10} and Δ[CoQ_{10}/TC] were further evaluated in women. Figure 3 shows the frequency of the different genotypes according to the HR/LR classification in the women. The rs2032582 GG and rs1761667 AA were associated with a “ΔCoQ_{10} HR” status, and rs3808607 GT/TT and rs2072183 CC were associated with a “Δ[CoQ_{10}/TC] HR” status.

Next, the women participants were divided into two groups by combining the four identified SNPs in women, and their serum levels of CoQ_{10}, ΔCoQ_{10}, and Δ[CoQ_{10}/TC] were compared (Figure 4). Group 1 consisted of the participants who had four or more of rs3808607 T, rs2072183 C, rs2032582 G, and rs1761667 A alleles, whereas group 2 consisted of the participants who had three or less of these alleles. The serum CoQ_{10} levels before and after supplementation and the ΔCoQ_{10} of group 1 were significantly higher than those of group 2 (Welch’s \( t \)-test, \( p = 0.021 \), \( p = 0.010 \), and \( p = 0.025 \), respectively; Figure 4). The Δ[CoQ_{10}/TC] was of borderline significance between the two groups (\( p = 0.051 \)), but group 1 showed a tendency for higher values than group 2. Each group of women was further subdivided into HR or LR according to ΔCoQ_{10} and Δ[CoQ_{10}/TC] average values to assess potential associations with the response to CoQ_{10} supplementation (Table 4).

The group with the above indicated four SNPs showed a significant association with the HR/LR classification of the Δ[CoQ_{10}/TC] (chi-squared test, \( p = 0.003 \)). The association between the group and the HR/LR classification of the ΔCoQ_{10} was borderline significant (chi-squared test, \( p = 0.063 \)). A similar subgroup analysis was performed with the above four SNPs in the men, but no statistical differences were detected between the two groups (Figure S2A). These results suggest that genotyping of the above four SNPs is useful for predicting the HR/LR classification of the serum ΔCoQ_{10} and Δ[CoQ_{10}/TC] levels prior to the long-term CoQ_{10} supplementation at least in women.
Figure 3. Genotypic frequency of the SNPs identified as correlated with the high-responders/low-responder (HR/LR) classification. The frequency of the genotypes of ABCB1 rs2032582 and CD36 rs1761667 associated with the ΔCoQ₁₀, and CYP7A1 rs3808607 and NPC1L1 rs2072183 with the Δ[CoQ₁₀/TC] in women were shown. ΔCoQ₁₀, increased serum coenzyme Q₁₀; Δ[CoQ₁₀/TC], cholesterol-adjusted increased serum CoQ₁₀; HR, high-responder; LR, low-responder.

Figure 4. Box plots showing the serum CoQ₁₀ levels at baseline and after 1 year of supplementation, ΔCoQ₁₀, and Δ[CoQ₁₀/TC] in women. The bottom of the box is the 25th percentile, the line that intersects the box is the median, the multiplication sign within the box is the mean, and the top of the box is the 75th percentile. Whiskers above and below the box represent the 10th and 90th percentiles, and the points above and below the whiskers indicate the outliers. Differences between the two groups were analyzed using Welch’s t-tests (p < 0.05). ΔCoQ₁₀, serum coenzyme Q₁₀; Δ[CoQ₁₀/TC], cholesterol-adjusted serum CoQ₁₀.
Table 4. Associations between group 1 and group 2 with HR/LR classification in women.

|                   | N                  | p-Value |
|-------------------|--------------------|---------|
| \( \Delta \text{CoQ}_{10} \) |                    |         |
| More than average (5.05 µmol/L) | 19 | 9 | 0.063 |
| Less than average | 19 | 23 |       |
| \( \Delta[\text{CoQ}_{10}/\text{TC}] \) |                    |         |
| More than average (952 µmol/mol) | 24 | 9 | 0.003 |
| Less than average | 14 | 23 |       |

Abbreviations: \( \Delta \text{CoQ}_{10} \), serum coenzyme Q\(_{10}\); \( \Delta[\text{CoQ}_{10}/\text{TC}] \), cholesterol-adjusted serum CoQ\(_{10}\); HR, high-responder; LR, low-responder.

4. Discussion

The present study successfully identified four SNPs involved in the large individual variability in serum \( \Delta \text{CoQ}_{10} \) and \( \Delta[\text{CoQ}_{10}/\text{TC}] \) levels after long-term supplementation in women. These SNPs are present in genes involved in cholesterol metabolism (CYP7A1 rs3808607) [42], CoQ\(_{10}\) absorption at the intestinal epithelium (NPC1L1 rs2072183) [29,43], CoQ\(_{10}\) efflux (ABCB1 rs2032582) [33], and cellular CoQ\(_{10}\) uptake (CD36 rs1761667) [32] (Table 3). Hence, classification by a combination of four SNPs may enable predicting HR or LR of CoQ\(_{10}\) supplementation in women (Table 4).

CYP7A1 encodes the rate-limiting enzyme, cholesterol 7α-hydroxylase, which regulates bile acids synthesis. Participants with rs3808607 GG show lower cholesterol levels with a higher level of bile acid synthesis after ingesting high-molecular-weight β-glucan [44]. Moreover, the GT/TT individuals have higher serum cholesterol levels than those harboring the GG genotype. NPC1L1 plays a pivotal role in intestinal cholesterol absorption in addition to its involvement in CoQ\(_{10}\) absorption. The hepatic expression of NPC1L1 was higher in rs2072183 CC individuals with gallstone disease than in those with CG/GG [45]. ABCB1 encodes the P-glycoprotein pump involved in drug efflux. In patients with colorectal cancer, rs2032582 GG genotype correlates with the highest P-glycoprotein expression in the tumor tissue [46]. In accordance with the ABCB1 expression, its rs2032582 polymorphism was associated with irinotecan-induced severe mucositis in metastatic colorectal cancer patients [47]. CD36 is a multi-ligand scavenger receptor whose primary function is to take up fatty acids and oxidized lipoproteins into cells [48]. The rs1761667 A allele reduces CD36 expression in monocytes [49] and lowers sensitivity to fatty acid molecules [50]. Based on these reports, it is reasonable to hypothesize that the T allele of rs3808607 is involved in raising serum CoQ\(_{10}\) levels accompanied by serum TC levels, while the C allele of rs2072183 is related to increased CoQ\(_{10}\) transport from the intestinal epithelium via increased NPC1L1 expression, and the A allele of rs1761667 decreases CoQ\(_{10}\) uptake from blood/tissue fluid into cells by downregulating CD36 expression; thus predicting the HR to CoQ\(_{10}\) supplementation. Notably, the G allele selection of rs2032582 showed a contrasting effect because it may increase the expression of ABCB1, resulting in accelerated efflux of molecules from the intestinal epithelium. Rs2032582 (G > T) is in linkage disequilibrium with rs1045642 (C > T) and rs1128503 (C > T), which may alter the higher-order structure of substrate/inhibitor interaction sites, resulting drug-specificity changes [51]. Thus, it may be inferred that ABCB1 translated from the T allele of rs2032582-containing mRNA can efflux more CoQ\(_{10}\) molecules than that from the G allele-containing mRNA. Further investigations should address the reason of this discrepancy.

In contrast, in men, none of the eight SNPs was associated with the HR/LR classification (Table 3). This could be attributed to the difference in the number of participants in each sex group; men participants (n = 38) were almost half of women participants (n = 70). Moreover, the serum CoQ\(_{10}\) levels after supplementation and \( \Delta \text{CoQ}_{10} \) values in three men participants (arrowheads in Figure S2) were too high, which were identified as outlier values by the Smirnov–Grubbs test (data not shown). Even when those three men participants, who belonged to both group 1 and group 2, were excluded from the analysis,
the serum CoQ₁₀ levels before and after supplementation, ∆CoQ₁₀, and ∆[CoQ₁₀/TC] remained statistically insignificant between the two groups ($p = 0.21, 0.068, 0.15,$ and 0.50, respectively; Figure S2B). However, those average values were higher in group 1 than in group 2, giving a possibility that classification based on the four SNPs might be useful for HR/LR prediction in both sexes. Alternatively, gender-specific effects due to estrogen-regulated gene expression could be responsible for the differences observed in response to CoQ₁₀ supplementation. Indeed, previous reports showed the gender-related modulation by rs3808607 [52,53], rs2072183 [54,55], rs2032582 [56], and rs1761667 [57]. In either case, whether the classification by the above four SNPs is useful would be clarified by performing the same study with a larger number of men participants.

However, this study has some limitations. First, only eight SNPs from seven genes were evaluated due to throughput limitations and the research budget. These SNPs were carefully selected based on reliable documentation from the PubMed/PMC database from the National Center for Biotechnology Information, USA. However, there are 20, 20, 36, 12, 18, and 178 PubMed-cited SNPs in SREBP2, HMGCR, APOB, CYP7A1, NPC1L1, and ABCB1, respectively (https://www.ncbi.nlm.nih.gov/snp, accessed on 3 January 2021), which may indicate that potentially important SNPs useful for the determination of HR/LR may have been left out from the analysis. Additionally, more suitable SNPs for HR/LR prediction may also exist in other genes. A genome-wide association study with the human SNP array may help find SNPs affecting serum CoQ₁₀ levels after long-term supplementation. Second, two types of reduced CoQ₁₀ supplements (a soft-encapsulated and a granulated form) were used according to the preferences of the participants. The participants also could switch between supplement types during the intervention. To increase the number of participants and ask them to follow the daily intake protocol of CoQ₁₀ supplementation for a long-term period, it was not possible to standardize the administered supplement form. Indeed, around 45% of the participants switched the supplement types during the intervention. Third, it was challenging to monitor the daily supplement intake of the participants for one year. We also provided the participants with a self-check calendar to record the daily intake of the CoQ₁₀ supplement when providing the supplements every three months. However, the participants sometimes forgot to record, which made it hard to monitor appropriately. Therefore, all we could do for relevant analyses was that the participants, whose serum ∆CoQ₁₀ levels were less than 1 µmol/L, were excluded from the analysis.

Currently, whether these SNPs and the HR/LR prediction are meaningful or useful to obtain conclusive evidence for the beneficial effects of CoQ₁₀ remains to be investigated in further detail. A combination of intervention studies with CoQ₁₀ and SNPs genotyping would help clarify this issue.

5. Conclusions

This study identified four SNPs in CYP7A1, NPC1L1, ABCB1, and CD36 involved in the regulation of serum CoQ₁₀ status after long-term supplementation of reduced CoQ₁₀ in women. Classification according to four SNP genotypes could help predict the response to CoQ₁₀ supplementations, thereby helping find reliable clinical evidence of the beneficial effects of CoQ₁₀ in future interventional studies.

Supplementary Materials: The following are available online at https://www.mdpi.com/2076-3921/10/3/431/s1, Figure S1: Genotyping of SREBP2 rs133291 (a), HMGCR rs3846663 (b), APOB rs1042034 (c), CYP7A1 rs3808607 (d), NPC1L1 rs2072183 (e), ABCB1 rs1045642 (f) and rs2032582 (g), and CD36 rs1761667 (h) by PCR-RFLP. Figure S2: Serum levels of CoQ₁₀, ∆CoQ₁₀, and ∆[CoQ₁₀/TC] of group 1 and group 2 in men.

Author Contributions: T.S. conceptualized the study; T.K. (Tetsu Kinoshita) and T.S. designed and conducted the clinical study; M.T., M.N., and T.S. collected the laboratory data; M.T. and T.S. wrote the original draft; and M.T., M.N, T.K. (Tetsu Kinoshita), T.K. (Takehiko Kaneko), and T.S. read, revised, and approved the final version of the manuscript. All authors have read and agreed to the published version of the manuscript.
Funding: This study was supported by the Grants-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science (Grant Numbers JP15K00840 and JP19K11797). M. Takahashi was a doctoral student financially supported by a Kazue Suzuki Doctor Course Scholarship. The funder had no role in the study design, collection, analysis, and interpretation of data; or writing the manuscript.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Wayo Women’s University Human Research Ethics Committee (Ethical approval number: 1614, Approval date: 14 October 2016).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgments: We thank Kenji Fujii of Kaneka Corporation for providing the encapsulated and granulated reduced CoQ10 supplement and for analyzing the serum CoQ10 concentrations.

Conflicts of Interest: The authors declare that they have no competing interests.

References

1. Crane, F.L. Biochemical Functions of Coenzyme Q10. *J. Am. Coll. Nutr.* 2001, 20, 591–598. [CrossRef]
2. Frei, B.; Kim, M.C.; Ames, B.N. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. *Proc. Natl. Acad. Sci. USA* 1990, 87, 4879–4883. [CrossRef]
3. López-Lluch, G.; Rodríguez-Aguilera, J.C.; Santos-Ocaña, C.; Navas, P. Is coenzyme Q a key factor in aging? *Mech. Ageing Dev.* 2010, 131, 225–235. [CrossRef] [PubMed]
4. Tian, G.; Sawashita, J.; Kubo, H.; Nishio, S.-Y.; Hashimoto, S.; Suzuki, N.; Yoshimura, H.; Tsuruoka, M.; Wang, Y.; Liu, Y.; et al. Ubiquinol-10 Supplementation Activates Mitochondria Functions to Decelerate Senescence in Senescence-Accelerated Mice. *Antioxid. Redox Signal.* 2014, 20, 2606–2620. [CrossRef]
5. Yan, J.; Fujii, K.; Yao, J.; Kishida, H.; Hosoe, K.; Sawashita, J.; Takeda, T.; Mori, M.; Higuchi, K. Reduced coenzyme Q10 supplementation decelerates senescence in SAMP1 mice. *Exp. Gerontol.* 2006, 41, 130–140. [CrossRef] [PubMed]
6. Varela-López, A.; Ochoa, J.J.; Llamas-Elvira, J.M.; López-Frias, M.; Planells, E.; Ramírez-Tortosa, M.; Ramírez-Tortosa, C.L.; Giampieri, F.; Battino, M.; Quiles, J.L. Age-Related Loss in Bone Mineral Density of Rats Fed Lifelong on a Fish Oil-Based Diet Is Avoided by Coenzyme Q10 Addition. *Nutrients* 2017, 9, 176. [CrossRef] [PubMed]
7. Chen, H.-C.; Huang, C.-C.; Lin, T.-J.; Hsu, M.-C.; Hsu, Y.-J. Ubiquinol Supplementation Alters Exercise Induced Fatigue by Increasing Lipid Utilization in Mice. *Nutrients* 2019, 11, 2550. [CrossRef] [PubMed]
8. Mantle, D.; Hargreaves, I. Coenzyme Q10 and Degenerative Disorders Affecting Longevity: An Overview. *Antioxidants* 2019, 8, 44. [CrossRef]
9. Deguchi, S.; Fujii, K.; Kurihara, T. The effect of the reduced form of coenzyme Q10 (ubiquinol, Kaneka QHTM) on QOL improvement in the elderly. *J. Clin. Ther. Med.* 2008, 24, 233–238.
10. Hofman-Bang, C.; Rehnqvist, N.; Swedberg, K.; Wiklund, I.; Åström, H. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. *J. Card. Fail.* 1995, 1, 101–107. [CrossRef]
11. Lister, R.E. An Open, Pilot Study to Evaluate the Potential Benefits of Coenzyme Q10 Combined with Ginkgo Biloba Extract in Fibromyalgia Syndrome. *J. Int. Med. Res.* 2002, 30, 195–199. [CrossRef] [PubMed]
12. Castro-Marrero, J.; Cordero, M.D.; Segundo, M.J.; Sáez-Francáis, N.; Calvo, N.; Román-Malo, L.; Aliste, L.; De Sevilla, T.F.; Alegre, J. Does Oral Coenzyme Q10 Plus NADH Supplementation Improve Fatigue and Biochemical Parameters in Chronic Fatigue Syndrome? *Antioxid. Redox Signal.* 2015, 22, 679–685. [CrossRef] [PubMed]
13. Castro-Marrero, J.; Sáez-Francáis, N.; Segundo, M.J.; Calvo, N.; Faro, M.; Aliste, L.; De Sevilla, T.F.; Alegre, J. Effect of coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation on maximum heart rate after exercise testing in chronic fatigue syndrome—a randomized, controlled, double-blind trial. *Clin. Nutr.* 2015, 34, 826–834. [CrossRef] [PubMed]
14. Banach, M.; Serban, C.; Sahebkar, A.; Ursoniu, S.; Rysz, J.; Munter, P.; Toth, P.P.; Jones, S.R.; Rizzo, M.; Glasser, S.P.; et al. Effects of coenzyme Q10 on statin-induced myopathy: A meta-analysis of randomized controlled trials. *Mayo Clin. Proc.* 2015, 90, 24–34. [CrossRef]
15. Kennedy, C.; Koller, Y.; Surkova, E. Effect of Coenzyme Q10 on statin-associated myalgia and adherence to statin therapy: A systematic review and meta-analysis. *Atherosclerosis* 2020, 299, 1–8. [CrossRef]
16. Negida, A.; Menshawy, A.; El Ashal, G.; ElFouly, Y.; Hani, Y.; Hegazy, Y.; El Ghonimy, S.; Fouda, S.; Rashad, Y. Coenzyme Q10 for Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis. *CNS Neurol. Disord. Drug Targets* 2016, 15, 45–53. [CrossRef]
17. Saboori, S.; Rad, E.Y.; Mardani, M.; Khosroshahi, M.Z.; Nouri, Y.; Falahi, E. Effect of Q10 supplementation on body weight and body mass index: A systematic review and meta-analysis of randomized controlled clinical trials. *Diabetes Metab. Syndr. Clin. Res. Rev.* 2019, 13, 1179–1185. [CrossRef]
18. Arenas-Jal, M.; Suñé-Negre, J.M.; García-Montoya, E. Coenzyme Q10 supplementation: Efficacy, safety, and formulation considerations. *Compr. Rev. Food Sci. Food Saf.* 2020, 19, 574–594. [CrossRef]

19. Barakat, A.; Shegokar, R.; Dittgen, M.; Müller, R.H. Coenzyme Q10 oral bioavailability: Effect of formulation type. *J. Pharm. Investig.* 2013, 43, 431–451. [CrossRef]

20. Hosoe, K.; Kitano, M.; Kishida, H.; Kubo, H.; Fujii, K.; Kitahara, M. Study on safety and bioavailability of ubiquinol (Kaneka QH™) after single and 4-week multiple oral administration to healthy volunteers. *Regul. Toxicol. Pharmacol.* 2007, 47, 19–28. [CrossRef]

21. Lopez-Lluch, G.; del Pozo-Cruz, J.; Sánchez-Cuesta, A.; Cortés-Rodriguez, A.B.; Navas, P. Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization. *Nutrient* 2019, 57, 133–140. [CrossRef]

22. Evans, M.; Baisley, J.; Bars, S.; Guthrie, N. A randomized, double-blind trial on the bioavailability of two CoQ10 formulations. *J. Funct. Foods* 2009, 1, 65–73. [CrossRef]

23. Pravst, I.; Aguilera, J.C.R.; Rodriguez, A.B.C.; Jazbar, J.; Locatelli, I.; Hristov, H.; Žmitek, K. Comparative Bioavailability of Different Coenzyme Q10 Formulations in Healthy Individuals. *Nutrients* 2020, 12, 784. [CrossRef]

24. Qin, B.; Liu, L.; Pan, Y.; Zhu, Y.; Wu, X.; Song, S.; Han, G. PEGylated Solanesol for Oral Delivery of Coenzyme Q10. *Biomembr.* 2017, 65, 3360–3367. [CrossRef]

25. Alehagen, U.; Aaseth, J.; Alexander, J.; Johansson, P.; Larsson, A. Supplemental selenium and coenzyme Q10 reduce glycation along with cardiovascular mortality in an elderly population with low selenium status—a four-year, prospective, randomised, double-blind placebo-controlled trial. *J. Trace Elements Med. Biol.* 2020, 61, 126541. [CrossRef]

26. Kinoshita, T.; Maruyama, K.; Tanigawa, T. The Effects of Long-Term Ubiquinol Intake on Improving the Quality of Life of Community Residents. *Funct. Foods Health Dis.* 2016, 6, 16. [CrossRef]

27. Mantle, D.; Dybring, A. Bioavailability of Coenzyme Q10: An Overview of the Absorption Process and Subsequent Metabolism. *Antioxidants* 2020, 9, 386. [CrossRef] [PubMed]

28. Nashimoto, S.; Takekawa, Y.; Takekuma, Y.; Sugawara, M.; Sato, Y. Transport via Niemann-Pick C1 Like 1 contributes to the intestinal absorption of ubiquinone. *Drug Metab. Pharmacokinet.* 2020, 35, 527–533. [CrossRef]

29. Takekawa, Y.; Sato, Y.; Yamaki, Y.; Imai, M.; Noto, K.; Sumi, M.; Takekuma, Y.; Iseki, K.; Sugawara, M. An Approach to Improve Intestinal Absorption of Poorly Absorbed Water-Insoluble Components via Niemann–Pick C1-Like 1. *Biol. Pharm. Bull.* 2016, 39, 301–307. [CrossRef] [PubMed]

30. Niklowitz, P.; Onur, S.; Fischer, A.; Laudes, M.; Palussen, M.; Menke, T.; Döring, F. Coenzyme Q10 serum concentration and redox status in European adults: Influence of age, sex, and lipoprotein concentration. *J. Clin. Biochem. Nutr.* 2016, 58, 240–245. [CrossRef] [PubMed]

31. Padilla-Lopez, S.; Jiménez-Hidalgo, M.; Martin-Montalvo, A.; Clarke, C.F.; Navas, P.; Santos-Ocaña, C. Genetic evidence for the requirement of the endocytic pathway in the uptake of coenzyme Q6 in Saccharomyces cerevisiae. *Biochim. Biophys. Acta (BBA) Biomembr.* 2009, 1788, 1238–1248. [CrossRef] [PubMed]

32. Anderson, C.M.; Kazantzis, M.; Wang, J.; Venkatraman, S.; Goncalves, R.L.S.; Quinlan, C.L.; Ngoc, V.A.-A.; Jastroch, M.; Benjamin, D.I.; Nie, B.; et al. Dependence of Brown Adipose Tissue Function on CD36-Mediated Coenzyme Q Uptake. *J. Agric. Food Chem.* 2020, 68, 709–735. [CrossRef] [PubMed]

33. Degenhardt, F.; Niklowitz, P.; Onur, S.; Fischer, A.; Laudes, M.; Palussen, M.; Menke, T.; Döring, F. Coenzyme Q10 metabolism and Coenzyme Q10 status in humans. *Regul. Toxicol. Pharmacol.* 2019, 68, 1788–1799. [CrossRef] [PubMed]

34. Ramos-Arellano, L.E.; Salgado-Bernabé, A.B.; Guzmán-Guzmán, I.P.; Salgado-Goytia, L.; Muñoz-Valle, J.F.; Parra-Rojas, I. CD36 haplotypes are associated with lipid profile in normal-weight subjects. *Lipids Health Dis.* 2013, 12, 167. [CrossRef]

35. Tomei, S.; Singh, P.; Mathew, R.; Mattei, V.; Garand, M.; Alwakeel, M.; Sharif, E.; Al Khodor, S. The Role of Polymorphisms in Vitamin D-Related Genes in Response to Vitamin D Supplementation. *Nutrients* 2020, 12, 2608. [CrossRef]

36. Degenhardt, F.; Niklowitz, P.; Szymczak, S.; Jacobs, G.; Lieb, W.; Menke, T.; Laudes, M.; Sko, T.; Weidinger, S.; Franke, A.; et al. Genome-wide association study of serum coenzyme Q10 levels identifies susceptibility loci linked to neuronal diseases. *Hum. Mol. Genet.* 2016, 25, 2881–2891. [CrossRef]

37. Fischer, A.; Schmelzer, C.; Rimbach, G.; Niklowitz, P.; Menke, T.; Döring, F. Association between genetic variants in the Coenzyme Q10 Transporter P-Glycoprotein. *J. Agric. Food Chem.* 2015, 63, 3360–3367. [CrossRef] [PubMed]

38. Ushikoshi-Nakayama, R.; Ryo, K.; Yamazaki, T.; Kaneko, M.; Sugano, T.; Ito, Y.; Matsumoto, N.; Saito, I. Effect of gummy candy containing ubiquinol on secretion of saliva: A randomized, double-blind, placebo-controlled parallel-group comparative study and an in vitro study. *PLoS ONE* 2019, 14, e0214495. [CrossRef]

39. Takahashi, M.; Nagata, M.; Kaneko, T.; Suzuki, T. Miso Soup Consumption Enhances the Bioavailability of the Reduced Form of Supplemental Coenzyme Q10. *J. Nutr. Metab.* 2020, 2020, 5349086. [CrossRef]

40. Meaney, S. Epigenetic regulation of cholesterol homeostasis. *Front. Genet.* 2014, 5, 311. [CrossRef]
43. Sahoo, S.; Aurich, M.K.; Jonsson, J.J.; Thiele, I. Membrane transporters in a human genome-scale metabolic knowledgebase and their implications for disease. *Front. Physiol.* 2014, 5, 91. [CrossRef] [PubMed]

44. Wang, Y.; Harding, S.V.; Thandapilly, S.J.; Tosh, S.M.; Jones, P.J.H.; Ames, N.P. Barley β-glucan reduces blood cholesterol levels via interrupting bile acid metabolism. *Br. J. Nutr.* 2017, 118, 822–829. [CrossRef]

45. Wu, J.; Cui, W.; Cai, Q.; Fei, J.; Zhang, S.-D.; Han, T.-Q.; Hu, H.; Jiang, Z.-Y. The NPC1L1 Polymorphism 1679C>G Is Associated with Gallstone Disease in Chinese Patients. *PLoS ONE* 2016, 11, e0147562. [CrossRef]

46. Samanian, S.; Mahjoubi, F.; Mahjoubi, B.; Mirzaee, R.; Azizi, R. MDR1 gene polymorphisms: Possible association with its expression and clinicopathology characteristics in colorectal cancer patients. *Asian Pac. J. Cancer Prev.* 2011, 12, 3141–3145. [PubMed]

47. Riera, P.; Artigas-Baleri, A.; Salazar, J.; Sebio, A.; Virgili, A.C.; Arranz, M.J.; Páez, D. ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. *Front. Pharmacol.* 2020, 11, 973. [CrossRef]

48. Silverstein, R.L.; Feabraio, M. CD36, a Scavenger Receptor Involved in Immunity, Metabolism, Angiogenesis, and Behavior. *Sci. Signal.* 2009, 2, re3. [CrossRef]

49. Love-Gregory, L.; Sherva, R.; Schappe, T.; Qi, J.-S.; McCrea, J.; Klein, S.; Connelly, M.A.; Abumrad, N.A. Common CD36 SNPs reduce protein expression and may contribute to a protective atherogenic profile. *Hum. Mol. Genet.* 2010, 20, 193–201. [CrossRef] [PubMed]

50. Sollai, G.; Melis, M.; Mastinu, M.; Pani, D.; Cosseddu, P.; Bonfiglio, A.; Crnjar, R.; Tepper, B.J.; Barbarossa, I.T. Human Tongue Electrophysiological Response to Oleic Acid and Its Associations with PROP Taster Status and the CD36 Polymorphism (rs1761667). *Nutrients* 2019, 11, 315. [CrossRef] [PubMed]

51. Kimchi-Sarfaty, C.; Oh, J.M.; Kim, I.-W.; Sauna, Z.E.; Calcagno, A.M.; Ambudkar, S.V.; Gottesman, M.M. A “Silent” Polymorphism in the MDR1 Gene Changes Substrate Specificity. *Science* 2007, 315, 525–528. [CrossRef] [PubMed]

52. Iwanicki, T.; Balcerzyk, A.; Niemiec, P.; Trautsolt, W.; Grzeszczak, W.; Ochaiska-Tyka, A.; Krauze, J.; Nowak, T.; Żak, I. The relationship between CYP7A1 polymorphisms, coronary artery disease & serum lipid markers. *Biomark. Med.* 2019, 13, 1199–1208. [CrossRef] [PubMed]

53. Srivastava, A.; Choudhuri, G.; Mittal, B. CYP7A1 (−204 A>C; rs3808607 and −469 T>C; rs3824260) promoter polymorphisms and risk of gallbladder cancer in North Indian population. *Metabolism* 2010, 59, 767–773. [CrossRef]

54. Miao, L.; Yin, R.-X.; Hu, X.-J.; Wu, D.-F.; Cao, X.-L.; Li, Q.; Yan, T.-T.; Aung, L.H.H.; Wu, J.-Z.; Lin, W.-X. Association of rs2072183 SNP and serum lipid levels in the Mulao and Han populations. *Lipids Health Dis.* 2012, 11, 61. [CrossRef]

55. Kim, D.S.; Burt, A.A.; Ranchalis, J.E.; Jarvik, E.R.; Jarvik, G.P. Novel gene-by-environment interactions: APOB and NPC1L1 variants affect the relationship between dietary and total plasma cholesterol. *J. Lipid Res.* 2013, 54, 1512–1520. [CrossRef] [PubMed]

56. Martinelli, M.; Scapoli, L.; Cura, F.; Rodia, M.T.; Ugolini, G.; Montroni, I.; Solmi, R. Colorectal cancer susceptibility: Apparent gender-related modulation by ABCB1 gene polymorphisms. *J. Biomed. Sci.* 2014, 21, 1–8. [CrossRef] [PubMed]

57. Chu, Y.; Lao, W.; Jin, G.; Dai, D.; Chen, L.; Kang, H. Evaluation of the relationship between CD36 and MARCO single-nucleotide polymorphisms and susceptibility to carotid atherosclerosis in a Chinese Han population. *Gene* 2017, 633, 66–70. [CrossRef]